Management of choroidal neovascularization in pathologic myopia: Combined therapy

Retina-Vitreus

Volumn 18, Issue 3, 2010, Pages 197-202

  Özdek, Şengül ^a   Şekeryapan, Berrak ^b   Ekici, Feyzahan ^a   Hasanreisoǧlu, Berati ^a  

^a GAZI UNIVERSITY   (Turkey)

^b RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Combination therapy; Pathologic myopia; Photodynamic therapy

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MYOPIA; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RETINA FOVEA; RETREATMENT; STROKE; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 78449287548     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hotchkiss ML, Fine SL.: Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91:177-183.
2. Cohen SY, Laroche A, Leguen Y, et al.: Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241-1244.
3. Ohno-Matsui K, Yoshida T, Futagami S, et al.: Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathological myopia. Br J Ophthalmol. 2003;87:570-573.
4. Secrétan M, Kuhn D, Soubrane G, et al.: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307-316
5. Verteporfin in Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology. 2001;108:841-852.
6. Blinder KJ, Blumenkranz MS, Bressler NM, et al.: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology. 2003;110:667-673.
7. Gelisken F, Inhoffen W, Hermann A, et al.: Verteporfin photodynamic therapy for extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2004;242:926-930. (Pubitemid 39562327)
8. Lam DS, Liu DT, Fan DS, et al.: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye. 2005;19:834-840.
9. Schnurrbusch UE, Jochmann C, Wiedemann P et al.: Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2005;243:829-833.
10. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
11. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
12. Emerson MV, Lauer AK, Flaxel CJ, et al.: Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439-444.
13. Yamamoto I, Rogers AH, Reichel E, et al.: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol. 2007;91:157-160.
14. Sakaguchi H, Ikuno Y, Gomi F, et al.: Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol. 2007;91:161-165. (Pubitemid 46202863)
15. Chan WM, Lai TY, Liu DT, et al.: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190-2196.
16. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al.: Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina. 2007;27:707-712.
17. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al.: Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. 2009;23:334-338.
18. Ikuno Y, Sayanagi K, Soga K, et al.: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94-100.
19. Gharbiya M, Allievi F, Mazzeo L, et al.: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009;147:84-93.
20. Chan WM, Lai TY, Wong AL, et al.: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularization secondary to pathological myopia: a pilot study. Br J Ophthalmol. 2007;91:174-179.
21. Lazic R, Gabric N.: Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:68-73.
22. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-134
23. Ozdek S, Hondur A, Gurelik G, et al.: Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol. 2005;26:127-133.
24. Ozdek S.: My way of assessment of neovascular AMD activity. When to treat? When to stop? Ophthalmol Times Europe, May 2009; e-pub, http://www.oteurope.com/ophthalmologytimeseu-rope//article/articledetail.jsp?ts= 111809040229&id=598240
25. Lazic R, Gabric N.: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179-1185.
26. Dhalla MS, Shah GK, Blinder KJ, et al.. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988-993.
27. Han DP, McAllister JT, Weinberg DV, et al.: Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond) 2009 Jun 5.